Aptar Pharma Inaugurates Site Expansion in Congers, NY
Aptar Pharma’s newly-expanded site will be used to complete premium injectable elastomeric component manufacturing.
Aptar Pharma’s site expansion in Congers, NY has been inaugurated on March 20, 2017 by Stephan Tanda, Aptar Group’s president and CEO; Salim Haffar, president of Aptar Pharma; and Alex Theodorakis, president Aptar Pharma North America. Aptar Pharma’s newly-expanded site will be used to complete premium injectable elastomeric component manufacturing. Some of the company’s customers in North America attended the event.
“The new expansion supports growth in three â¨directions,” explained Bas van Buijtenen,â¨president, Injectables Division, Aptar Pharma. “It adds capacity to our network of global manufacturing sites and will be equipped with the latest technologies to meet growing quality requirements. The proximity to our North American customer base improves our service and responsiveness.”
Following this event, Aptar Pharma will welcome current and future customers and partners during the Drug, Chemical & Associated Technologies Association (DCAT) Week and Interphex, at booth 1734.
Source: Aptar Pharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
